TIANYU PHARM: The company's bulk lisinopril raw material has obtained the CEP certificate

TIANYU PHARM announced that the company has received the European Pharmacopoeia suitability certification for the active pharmaceutical ingredient Brilinta issued by the European Medicines Agency. The acquisition of this certificate indicates that the active pharmaceutical ingredient meets the quality requirements of the European Pharmacopoeia, allowing it to be sold in the European market and other regulated markets that recognize the CEP certificate, which will have a positive impact on the company's efforts to further enrich its product offerings and expand into international markets